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Abstract
OBJECTIVES: The purpose of this study was to assess whether MSCTA may be useful for risk
stratification of patients with suspected CAD at intermediate pre-test likelihood according to Diamond
and Forrester. Design and PATIENTS: MSCTA images were evaluated for the presence of significant
CAD in 316 included patients (60% male, average age 57+/-11 years) with suspected CAD and an
intermediate pre-test likelihood according to Diamond and Forrester. Patients were followed in time for
the occurrence of an event. MAIN OUTCOME MEASURES: A combined endpoint of all cause
mortality, non-fatal infarction, and unstable angina requiring revascularization. RESULTS: Significant
CAD was observed in 89 patients (28%), whereas normal MSCTA or non-significant CAD was
observed in the remaining 227 (72%) patients. During follow-up (median 621 days (95%-confidence
interval: 408-835) an event occurred in 13 patients (4.8%). The annualized event rate was 0.8% in
patients with normal MSCT, 2.2% in patients with non-significant CAD and 6.5% in patients with
significant CAD. Moreover, MSCTA remained a significant predictor (p<0.05) of events after
multivariate correction. CONCLUSIONS: Our results suggest that in an intermediate pre-test likelihood
population, MSCTA is highly effective in re-stratifying patients into either a low or high post-test risk
group. These results further emphasize the usefulness of non-invasive imaging with MSCTA in this
patient population.
doi:10.1136/hrt.2009.167353 
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Abstract 
 
Objectives:  The purpose of this study was to assess whether MSCTA may be 
useful for risk stratification of patients with suspected CAD at intermediate pre-
test likelihood according to Diamond and Forrester. 
Design and Patients: MSCTA images were evaluated for the presence of 
significant CAD in 316 included patients (60% male, average age 57±11 years) 
with suspected CAD and an intermediate pre-test likelihood according to 
Diamond and Forrester. Patients were followed in time for the occurrence of an 
event. 
Main outcome measures: A combined endpoint of all cause mortality, non-fatal 
infarction, and unstable angina requiring revascularization. 
Results: significant CAD was observed in 89 patients (28%), whereas normal 
MSCTA or non-significant CAD was observed in the remaining 227 (72%) 
patients. During follow-up (median 621 days (95%-confidence interval: 408-835) 
an event occurred in 13 patients (4.8%). The annualized event rate was 0.8% in 
patients with normal MSCT, 2.2% in patients with non-significant CAD and 6.5% 
in patients with significant CAD. Moreover, MSCTA remained a significant 
predictor (p<0.05) of events after multivariate correction.  
Conclusions: Our results suggest that in an intermediate pre-test likelihood 
population, MSCTA is highly effective in re-stratifying patients into either a low or 
high post-test risk group. These results further emphasize the usefulness of non-
invasive imaging with MSCTA in this patient population. 
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INTRODUCTION 
 
Coronary artery disease (CAD) is a leading cause of mortality and morbidity 
worldwide. The diagnosis and management of this disease is increasingly 
dependent on non-invasive imaging strategies. With the introduction of multi-slice 
computed tomography coronary angiography (MSCTA) non-invasive assessment 
of coronary anatomy has become possible, allowing early identification of 
atherosclerosis. MSCTA has a high diagnostic accuracy for the detection of 
significant CAD (≥50% luminal narrowing) on conventional coronary 
angiography,[1 2 3 4 5 6 7] and may be particularly useful for diagnosis in 
patients with an intermediate pre-test likelihood for significant CAD.[8] Although 
the prognostic value of MSCTA has been evaluated in previous studies [7 9 10 11 
12 13 14 15 16], no studies have specifically addressed the target population for 
MSCTA. The purpose of this study therefore was to assess if MSCTA may be 
useful for risk stratification in patients with suspected CAD and an intermediate 
pre-test likelihood.
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METHODS 
 
The study population consisted of 331 patients with suspected CAD and 
an intermediate pre-test likelihood. Patients were clinically referred for further 
cardiac assessment as part of an ongoing study protocol addressing the 
prognostic value of MSCTA. From this prospective registry, results addressing 
the incremental prognostic value of MSCTA over myocardial perfusion imaging 
have been recently published. [13] 
Baseline clinical demographic values were recorded from the electronic 
patient file based on physician documented history. Symptoms were classified as 
typical angina, atypical angina, non-anginal chest pain and asymptomatic. 
Typical anginal chest pain was defined as combination of: 1) discomfort in the 
anterior chest, neck, shoulders, jaw, or arms; 2) precipated by phycial exertion or 
psychic stress; and 3) relieved by rest or nitroglycerin within minutes. Atypical 
chest pain was defined as chest pain with two 2 of these 3 factors and non-
anginal chest pain was defined as chest pain with less than 2 of these 3 
factors.[17] Pre-test likelihood was defined according to Diamond and Forrester 
criteria which are based on age, gender and symptomatic status.[18] 
Intermediate likelihood was defined as a pre-test likelihood between 13.4 and 
87.2%. In addition, asymptomatic diabetic patients were also classified as having 
an intermediate pre-test likelihood according to the increased prevalence of CAD 
and increased risk of events in this population.[19 20 21] Exclusion criteria were: 
cardiac arrhythmias, renal insufficiency (defined as a glomerular filtration rate 
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<30 ml/min), known hypersensitivity to iodine contrast media, and pregnancy. In 
addition, patients with an uninterpretable MSCTA examination were excluded 
from further analysis. The study was approved by the local ethics committee in 
both participating centers. 
Patients were scanned using a 64-slice CT scanner (Aquillion64, Toshiba 
Medical Systems, Tokyo, Japan; General Electrics LightSpeed VCT, Milwaukee, 
WI, US; or Sensation64, Siemens, Forchheim, Germany). For each patient, the 
heart rate and blood pressure were monitored before the scan. In the absence of 
contraindications, patients with a heart rate exceeding the threshold of 65 beats 
per minute were administered beta-blocking medication (50-100 mg metoprolol, 
oral or 5-10 mg metoprolol, intravenous). The contrast enhanced helical scan 
was performed using 80-140 ml of non-ionic contrast agent (Xenetix 300; 
Iomeron 400; or Iodixanol 370) administered at a flow rate of 3.5-5 ml/s followed 
by a bolus of saline flush (30-50 ml at 3.5-5 ml/s). All scan parameters have been 
previously published.[22 23 24] 
Datasets were reconstructed from the retrospectively gated raw data. 
Images were reconstructed with an effective slice thickness of 0.3, 0.5 or 0.625 
mm with the Toshiba, Siemens, and GE systems respectively. Coronary arteries 
were evaluated using the reconstruction dataset with the least motion artifacts, 
typically an end-diastolic phase. Post-processing was performed on dedicated 
workstations (Vitrea2, Vital Images, USA , Advantage, GE healthcare, USA, 
Leonardo, Siemens, Germany). The interpretation of MSCTA angiograms was 
performed in a standardized manner using the axial slices, curved multiplanar 
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reconstructions (MPR), and maximum intensity projections (MIP). MSCTA 
examinations were scored on a patient basis by two experienced observers in 
each center, based on the maximum luminal diameter stenosis. Discrepancies in 
interpretation were resolved by consensus. Normal MSCTA was defined as 
completely normal anatomy, non-significant stenosis was defined as the 
presence of luminal narrowing with a maximal luminal diameter stenosis <50%, 
and significant stenosis was defined as the presence of an atherosclerotic lesion 
exceeding the threshold of ≥50% luminal narrowing. The effective dose of the CS 
and MSCTA scans was estimated from the product of the dose-length product 
and an organ weighing factor [k=0.014 mSv x (mGy x cm)-1] for the chest as the 
investigated anatomical region.[25]  
Patient follow-up data were gathered using clinical visits or standardized 
telephone interviews. The following events were regarded as clinical endpoints: 
all cause mortality, non-fatal myocardial infarction, and unstable angina requiring 
revascularization. Two combined endpoints were used: a combined endpoint of 
all events; and a combined hard endpoint including only all cause mortality and 
non-fatal myocardial infarction. Non-fatal infarction was defined based on criteria 
of typical chest pain, elevated cardiac enzyme levels, and typical changes on the 
ECG. Unstable angina was defined according to the European Society of 
Cardiology guidelines as acute chest pain with or without the presence of ECG 
abnormalities, and negative cardiac enzyme levels.[26] Patients with stable 
complaints undergoing an early elective revascularization within 60 days after 
MSCTA were excluded from the survival analysis. 
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Continuous variables were expressed as mean and standard deviation, 
and categorical baseline data were expressed in numbers and percentages. Cox 
regression analysis was used to determine the prognostic value of MSCTA. First 
univariate analysis of baseline clinical variables and MSCTA variables was 
performed using a composite endpoint of all cause mortality, non-fatal infarction, 
and unstable angina requiring revascularization. For each variable a hazard ratio 
with a 95%-confidence interval (95%-CI) was calculated. Finally a multivariate 
model was created using backward stepwise selection to assess the independent 
predictive value of MSCTA corrected for baseline clinical variables. At each step, 
the least significant variable was discarded from the model, until all variables in 
the model reached a p-value <0.25. 
Cumulative event rates for MSCTA were obtained by the Kaplan-Meier 
method, and the survival curves were compared using the log-rank test. 
Statistical analyses were performed using SPSS software (version 12.0, SPSS 
Inc, Chicago, IL, USA). A p-value <0.05 was considered statistically significant. 
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RESULTS 
 
Patient characteristics: The study population, derived from our 
prospective registry,[27] consisted of 331 patients with suspected CAD and an 
intermediate pre-test likelihood. The MSCTA examination was uninterpretable in 
15 patients (4.5%). Reasons for uninterpretability were the presence of motion 
artifacts, increased noise due to high body mass index, and breathing. After 
exclusion of these patients, a total of 316 patients remained for analysis. The 
average age of the study cohort was 57±11 years and 60% of patients were men. 
Patients presented with asymptomatic diabetes (25%) non-anginal chest pain 
(22%), atypical chest pain (48%), and typical chest pain (5%). A complete 
overview of the baseline characteristics of the study population is presented in 
Table 1. 
 
MSCT results: During MSCTA image acquisition, an average heart rate of 
63±10 beats per minute was recorded. MSCTA was classified as normal in 85 
(27%) of patients. Atherosclerosis was detected in the remaining 231 (73%) 
patients, classified as non-significant CAD (<50% luminal narrowing) in 142 
(45%) and significant CAD (≥50% luminal narrowing) in 89 (28%) patients.(Figure 
1) The estimated average radiation dose for the coronary angiography protocol 
was 18.1±5.9 mSv and the estimated radiation dose for the CS protocol was 
1.4±0.6 mSv. 
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Follow-up results: In total, 26 (8%) patients were lost to follow-up and 21 
(7%) patients underwent early revascularization. In the remaining 269 patients 
the median follow-up time achieved was 621 days (25-75th percentile: 408-835). 
During the follow-up period an event occurred in 13 patients (5%). All cause 
mortality was reported in 5 patients (2%), whereas non-fatal myocardial infarction 
occurred in 3 patients (1%) and 5 patients (2%) were revascularized due to 
unstable angina pectoris. In the excluded patients with an early revascularization 
myocardial infarction occurred in 1 of 21 patients. 
 
Event rates: In patients with a normal MSCTA an annualized event rate 
(annualized event rate for hard events between parentheses) of 0.8% (0%) was 
observed, while in patients with atherosclerosis (non-significant and/or significant 
CAD) the annualized event rate was 3.5% (2.6%). Significant CAD (≥50% luminal 
narrowing) on MSCTA resulted in an event rate of 6.5% (4.6%). The total event 
rates (all cause mortality, non-fatal myocardial infarction and unstable angina 
requiring revascularization) and the hard event rates (all cause mortality and non-
fatal myocardial infarction) in all patients and stratified according to MSCTA are 
shown in Figure 2. 
 
Survival analysis: Baseline univariate predictors of events are listed in 
Table 2. Significant CAD (≥50% luminal narrowing) was the best univariate 
predictor of events with a hazard ratio of 3.9 (95%-confidence interval: 1.3-11.7). 
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After correcting for smoking in a multivariate model this variable remained an 
independent predictor of events.(Table 2) The Kaplan-Meier survival analysis in 
Figure 3 further illustrates the usefulness of ≥50% luminal narrowing on MSCTA 
as a cutoff for risk stratification. A significant difference (Logrank P-value 0.008) 
in survival was observed between patients with normal or non-significant CAD 
and patients with significant CAD (≥50% luminal narrowing) on MSCTA. Similar 
results were obtained when using a combined hard endpoint of all cause 
mortality and non-fatal myocardial infarction (Logrank P-value 0.0077).(Figure 3) 
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DISCUSSION 
 
The main finding of the current study is that in an intermediate pre-test 
likelihood population, MSCTA has a good prognostic value and may effectively 
identify patients at higher or lower risk for coronary events. These results further 
emphasize the usefulness of non-invasive imaging with MSCTA in this patient 
population. 
MSCTA is increasingly used in the diagnosis of CAD, and may be 
specifically useful for the rule out of CAD. The diagnostic accuracy of MSCTA 
has been studied extensively, and in early single center studies an average 
weighted sensitivity of 97.5 (95%-confidence interval 96-99) and specificity of 91 
(95%-confidence interval 87.5-95) has been observed.[5] More recently several 
prospective multi-center studies have been published showing similar 
sensitivities and specificities.[1 3 4] Importantly however, in the majority of these 
diagnostic accuracy studies patients were included who were referred for 
conventional diagnostic coronary angiography and thus with high pre-test 
probability. Accordingly, when interpreting these observations, it is important to 
take into account the pre-test probability, as according to Bayes theorem, pre-
test probability may have a major influence on the positive and negative 
predictive value. With increasingly higher pre-test probability, the prevalence of 
disease is higher and as a consequence the positive predictive value will 
increase, with a subsequent decrease in negative predictive value. Conversely, 
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in lower pre-test probability populations, with lower disease prevalence, positive 
predictive value will decrease, but negative predictive value will improve.  
The relationship between pre-test probability and the diagnostic accuracy 
of MSCTA was recently studied by Meijboom et al. among patients with a high, 
intermediate, or low pre-test likelihood. In patients with a high pre-test likelihood 
for CAD, the post-test probability for significant CAD after MSCT was not 
substantially different from the pre-test probability. As a result, a normal 
examination did not result in sufficient reduction of post-test probability to reliably 
rule out the presence of significant CAD. These observations indicate that the 
clinical value of MSCTA is limited in this patient group. In contrast, in patients 
with a low and intermediate pre-test likelihood, a negative MSCTA scan was able 
to reduce the post test probability of CAD to 0%.[28] The effectiveness of 
MSCTA in patients with an intermediate pre-test likelihood was also confirmed by 
Henneman et al.[29] The authors assessed the prevalence of completely normal 
MSCTA, and thus the efficacy to rule out CAD, in patients with suspected CAD 
and related these observations to the pre-test likelihood of CAD. The authors 
showed that normal MSCTA was observed in only 17% of patients with a high 
pre-test likelihood further underlining the limited clinical value in those patients. 
Conversely, MSCTA was able to rule out the presence of atherosclerosis in 33% 
of patients with an intermediate pre-test likelihood. 
However, in addition to diagnosis, prognostification is an important 
component of imaging tests and determines subsequent management. Thus far, 
several prognostic studies have addressed the potential prognostic value of 
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MSCTA. [7 9 10 11 13] However, most of these observations have been derived 
from heterogeneous patient populations including patients with known CAD. In 
several more recent publications the prognostic value of MSCT has been 
determined specifically in patients with suspected CAD.[14 15 16] In the study by 
Carrigan et al. 227 patients without documented CAD were included.[16] The 
absence of obstructive CAD was associated with a 99% freedom from cardiac 
death, myocardial infarction and revascularization during an average of 2.3 years 
of follow-up. In patients with one or more vessels with obstructive CAD a 
significantly increased event rate was observed (Log rank p-value 0.01). Similar 
findings were recently reported by Hadamitzky et al. [14]  
Although these observations underline the usefulness of MSCT for 
prognosis in patients with suspected CAD, dedicated data in the target 
population for MSCT, patients with an intermediate pre-test likelihood, are 
lacking. Importantly, the results of the current study confirm the prognostic value 
of MSCT in this particular patient population as MSCTA was shown to be highly 
effective for risk stratification. Indeed, hard event rates were <1% for patients 
without significant stenosis on MSCTA, indicating that these patients may be 
safely reassured. In contrast, the presence of a significant stenosis implied a 
substantially increased risk approaching 5% of coronary events.  
Several limitations need to be acknowledged. Even though the diagnostic 
accuracy of MSCTA is high, uninterpretable images are still being encountered in 
a small percentage of patients due to motion because of high or irregular heart 
rates or breathing during the examination. It is however anticipated that the 
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number of uninterpretable studies will continue to decrease with newer 
generation scanners. Currently 64-slice MSCTA is still associated with a high 
radiation exposure, although the radiation dose of MSCTA will decrease with the 
use of dedicated dose reduction techniques that have recently become 
available.[30 31 32 33] Importantly, low-dose computed tomography with 
prospective ECG-triggering has recently been shown to reduce radiation burden 
while maintaining diagnostic image quality and a high diagnostic accuracy.[34 35] 
In conclusion, our results suggest that in an intermediate pre-test 
likelihood population, MSCTA is highly effective in re-stratifying patients into 
either a low or high post-test risk group. These results further emphasize the 
usefulness of non-invasive imaging with MSCTA in this patient population. 
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Figure legends 
 
Figure 1: Pie chart illustrating the distribution of MSCTA findings.    
Abbreviations: CAD: coronary artery disease; MSCTA: multi-slice 
computed tomography coronary angiography. 
Figure 2: The annualized event rate in all patients and stratified according to 
MSCTA results. Panel A: Bar graph for all events (all cause mortality, 
non-fatal myocardial infarction, and unstable angina requiring 
revascularization); Panel B: Bar graph for hard events (all cause 
mortality, and non-fatal myocardial infarction).                    
Abbreviation: CAD: coronary artery disease; MSCTA: multi-slice 
computed tomography coronary angiography. 
Figure 3: Kaplan-Meier survival curves in patients with normal or non-significant 
CAD (<50% luminal narrowing) compared to patients with significant 
CAD (≥50% luminal narrowing). Panel A: Kaplan-Meier curves for all 
events (all cause mortality, non-fatal myocardial infarction, and 
unstable angina requiring revascularization); Panel B: Kaplan-Meier 
curves for hard events (all cause mortality, and non-fatal myocardial 
infarction).                                                                                    
Abbreviation: CAD: coronary artery disease. 
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Tables 
Abbreviations: BMI: body mass index; CAD: coronary artery disease. 
Table 1. Patient characteristics  
 Total 
 
n = 316 
Gender (male)  190 (60.1%) 
Age (yrs) 57±11 
Risk Factors  
  Diabetes 127 (40.2%) 
  Hypertension 174 (55.1%) 
  Hypercholesterolemia 125 (39.6%) 
  Family history CAD 123 (38.9%) 
  Current Smoking 102 (32.3%) 
  Obesity (BMI ≥ 30) 71 (22.5%) 
Symptoms  
  Asymptomatic 78 (24.7%) 
  Dyspnoea 34 (10.8%) 
  Non-anginal chest pain 36 (11.4%) 
  Atypical chest pain 151 (47.8%) 
  Typical chest pain 17 (5.4%) 
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Abbreviations: BMI: body mass index; CAD: coronary artery disease; HR: 
hazard ratio. 
 
 
 
Table 2. Univariate and Multivariate predictors of events 
 Univariate analysis Multivariate analysis 
 HR (95%-CI) p-value HR (95%-CI) p-value 
Risk factors     
  Gender (male) 0.840 (0.282-2.503) 0.754   
  Age (yrs) 1.006 (0.957-1.058) 0.814   
  Diabetes 0.987 (0.322-3.019) 0.981   
  Hypertension 0.856 (0.288-2.551) 0.781   
  Hypercholesterolemia 1.253 (0.421-3.729) 0.685   
  Family history CAD 0.965 (0.316-2.951) 0.951   
  Current Smoking 2.546 (0.855-7.576) 0.093   
  Obesity (BMI ≥ 30) 1.274 (0.349-4.654) 0.714   
MSCTA     
  Atherosclerosis 4.718 (0.613-36.301) 0.136   
  Significant CAD 3.924 (1.318-11.682) 0.014 3.460 (1.142-10.480) 0.028 
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